Table 3.
Production of ginsenosides in four genetically engineered strains
| Substrate (concentration in medium, mg/L) | Products (yield, mg/L and conversion, w/w%) |
|||
|---|---|---|---|---|
| BL21*-p2GT95 | BL21*-pGTK1 | BL21*-pGTC1 | BL21*-p2GT95K1 | |
| 20(R)-PPD (3.64 ± 0.32) | 20(R)-CK (0.57 ± 0.04, 15.7%) | 20(R)-Rh2 (0.13 ± 0.007, 3.6%) | 20(R)-Rh2 (0.06 ± 0.01, 1.6%) | 20(R)-CK (0.44 ± 0.04, 12.1%) 20(R)-F2 (0.06 ± 0.01, 1.6%) |
| 20(R)-Rh23) | 20(R)-F2 (1.08 ± 0.21) | −1) | – | −2) |
| 20(R)-Rg34) | 20(R)-Rd (0.01) | – | – | — |
| 20(R)-PPT (19.53 ± 0.68) | 20(R)-F1 (6.48 ± 0.03, 33.2%) 20(R)-Rg1 (0.2 ± 0.01, 1.0%) |
– | – | – |
| 20(S)-PPD (3.64 ± 0.29) | 20(S)-CK (0.36 ± 0.07, 9.9%) | 20(S)-Rh2 (0.77 ± 0.02, 21.2%) | 20(S)-Rh2 (0.3 ± 0.03, 8.2%) | 20(S)-CK (0.61 ± 0.06, 16.8%) 20(S)-F2 (0.36 ± 0.01, 9.9%) |
| 20(S)-Rh25) | 20(S)-F2 (1.46 ± 0.12) | – | – | — |
| 20(S)-Rg3 (6.71 ± 0.11) | 20(S)-Rd (0.36 ± 0.04, 5.4%) | – | – | — |
| 20(S)-PPT (23.31 ± 0.43) | 20(S)-F1 (6.34 ± 0.18, 27.2%) 20(S)-Rg1 (0.23 ± 0.01, 1.0%) |
– | – | — |
| 20(S)-CK (5.47 ± 0.20) | – | 20(S)-F2 (0.62 ± 0.12, 11.3%) | 20(S)-F2 (0.36 ± 0.03, 6.6%) | — |
CK, compound K; ESI, electrospray ionization; PPD, protopanaxadiol; PPT, protopanaxatriol; UPLC, ultra performance liquid chromatography.
1) –, not produced.
2) —, the experiment was not implemented.
3)–5) These substrates had low solubility in water, which was not detected by (UPLC-ESI-MS).